Evidence map›Paper›PMID 39181389›Full record

ArticleBiological psychiatry2025

Unique Functional Neuroimaging Signatures of Genetic Versus Clinical High Risk for Psychosis.

Charles H Schleifer, Sarah E Chang, Carolyn M Amir, Kathleen P O'Hora, Hoki Fung, Jee Won D Kang, Leila Kushan-Wells, Eileen Daly, Fabio Di Fabio, Marianna Frascarelli and 18 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Charles H SchleiferDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California.
Sarah E ChangDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California.
Carolyn M AmirDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California.
Kathleen P O'HoraDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California.
Hoki FungDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California.
Jee Won D KangDepartment of Psychology, University of California, Los Angeles, Los Angeles, California.
Leila Kushan-WellsDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California.
Eileen DalyDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Fabio Di FabioDepartment of Human Neurosciences, Sapienza University, Rome, Italy.
Marianna FrascarelliDepartment of Human Neurosciences, Sapienza University, Rome, Italy.
Maria GudbrandsenDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; Centre for Research in Psychological Wellbeing, School of Psychology, University of Roehampton, London, United Kingdom.
Wendy R KatesDepartment of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, New York.
Declan MurphyDepartment of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Jean AddingtonDepartment of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Alan AnticevicManifest Technologies, New Haven, Connecticut; Department of Psychiatry, Yale University, New Haven, Connecticut.
Kristin S CadenheadDepartment of Psychiatry, University of California, San Diego, San Diego, California.
Tyrone D CannonDepartment of Psychiatry, Yale University, New Haven, Connecticut; Department of Psychology, Yale University, New Haven, Connecticut.
Barbara A CornblattDepartment of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
Matcheri KeshavanDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Daniel H MathalonDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco and Veterans Affairs San Francisco Health Care System, San Francisco, California.
Diana O PerkinsDepartment of Psychiatry, University of North Carolina, Chapel Hill, North Carolina.
William S StoneDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Elaine WalkerDepartment of Psychology, Emory University, Atlanta, Georgia.
Scott W WoodsDepartment of Psychiatry, Yale University, New Haven, Connecticut.
Lucina Q UddinDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California.
Kuldeep KumarCentre de Recherche du CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.
Gil D HoftmanDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California.
Carrie E BeardenDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California; Department of Psychology, University of California, Los Angeles, Los Angeles, California. Electronic address: cbearden@mednet.ucla.edu.

Funding

UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
STRESS AND EMOTIONAL REACTIVITYP50MH066286 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NUECHTERLEIN, KEITH H · 2003 to 2014
$18.6M
1/9 Predictors and Mechanisms of Conversion to PsychosisU01MH081902 · NIMH · YALE UNIVERSITY · PI CANNON, TYRONE D · 2008 to 2018
$12.4M
A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for SchizophreniaU01MH121766 · NIMH · YALE UNIVERSITY · PI KRYSTAL, JOHN H. · 2019 to 2022
$11.8M
Training U54EB020403 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2014 to 2018
$10.1M
Vulnerability to Progression SchizophreniaP50MH080272 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WOO, TSUNGUNG · 2007 to 2011
$9.9M
5/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082004 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PERKINS, DIANA O. · 2008 to 2018
$7.5M
Biomarkers for Psychosis in Velocardiofacial SyndromeR01MH064824 · NIMH · UPSTATE MEDICAL UNIVERSITY · PI KATES, WENDY · 2002 to 2015
$7.3M
Administrative Supplement Harmonization of At Risk Multisite Observational Networks for Youth(HARMONY)U01MH081928 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI STONE, WILLIAM SETH · 2008 to 2018
$7.1M
Neurodevelopment and Psychosis in the 22q11.2 Deletion SyndromeR01MH085953 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEARDEN, CARRIE E · 2010 to 2020
$6.2M
4/9-Predictors and Mechanisms of Conversion to PsychosisU01MH081857 · NIMH · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CORNBLATT, BARBARA A. · 2008 to 2018
$6.2M
8/9 Predictors and Mechanisms of Conversion to PsychosisU01MH082022 · NIMH · YALE UNIVERSITY · PI WOODS, SCOTT W · 2008 to 2018
$6.0M
NIBIB NIH HHS U54 EB020403NIGMS NIH HHS T32 GM008042NIH HHS DP5 OD012109NIMH NIH HHS F31 MH133326NIMH NIH HHS K23 MH129826NIMH NIH HHS K24 MH076191NIMH NIH HHS P50 MH066286NIMH NIH HHS P50 MH080272NIMH NIH HHS R01 MH060720NIMH NIH HHS R01 MH064824NIMH NIH HHS R01 MH065481NIMH NIH HHS R01 MH085953NIMH NIH HHS R01 MH108590NIMH NIH HHS R01 MH112746NIMH NIH HHS R21 MH116473NIMH NIH HHS R37 MH085953NIMH NIH HHS U01 MH081857NIMH NIH HHS U01 MH081902NIMH NIH HHS U01 MH081928NIMH NIH HHS U01 MH081984NIMH NIH HHS U01 MH081988NIMH NIH HHS U01 MH082004NIMH NIH HHS U01 MH082022NIMH NIH HHS U01 MH121766NINDS NIH HHS T32 NS048004
6 · The paper itself

Abstract

background22q11.2 deletion syndrome (22qDel) is a copy number variant that is associated with psychosis and other neurodevelopmental disorders. Adolescents who are at clinical high risk for psychosis (CHR) are identified based on the presence of subthreshold psychosis symptoms. Whether common neural substrates underlie these distinct high-risk populations is unknown. We compared functional brain measures in 22qDel and CHR cohorts and mapped the results to biological pathways.

methodsWe analyzed 2 large multisite cohorts with resting-state functional magnetic resonance imaging data: 1) a 22qDel cohort (n = 164, 47% female) and typically developing (TD) control participants (n = 134, 56% female); and 2) a cohort of CHR individuals (n = 240, 41% female) and TD control participants (n = 149, 46% female) from the NAPLS-2 (North American Prodrome Longitudinal Study-2). We computed global brain connectivity (GBC), local connectivity (LC), and brain signal variability (BSV) across cortical regions and tested case-control differences for 22qDel and CHR separately. Group difference maps were related to published brain maps using autocorrelation-preserving permutation.

resultsBSV, LC, and GBC were significantly disrupted in individuals with 22qDel compared with TD control participants (false discovery rate-corrected q < .05). Spatial maps of BSV and LC differences were highly correlated with each other, unlike GBC. In the CHR group, only LC was significantly altered versus the control group, with a different spatial pattern than the 22qDel group. Group differences mapped onto biological gradients, with 22qDel effects being strongest in regions with high predicted blood flow and metabolism.

conclusions22qDel carriers and CHR individuals exhibited different effects on functional magnetic resonance imaging temporal variability and multiscale functional connectivity. In 22qDel carriers, strong and convergent disruptions in BSV and LC that were not seen in CHR individuals suggest distinct functional brain alterations.

Indexed as

BrainFunctional NeuroimagingMagnetic Resonance ImagingPsychotic DisordersAdolescentCase-Control StudiesChildCohort StudiesDiGeorge SyndromeFemaleHumansLongitudinal StudiesMaleProdromal SymptomsYoung Adult22q11.2 deletion syndromeBrain signal variabilityClinical high riskFunctional connectivityNeuromapsPsychosis

Identifiers

PMID39181389
PMCPMC12186773

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.